Christopher Ngai

Christopher Ngai has an extensive work experience in the field of market access and pricing. Christopher is currently serving as the Vice President of Market Access at Calliditas Therapeutics AB since March 2020. Prior to this, they held the position of Vice President of Global Market Access at BioCryst Pharmaceuticals, Inc. from March 2019 to February 2020.

Christopher has also worked at Bayer for a significant amount of time, starting in September 2012 as the Market Access Strategy Leader. Christopher led the Access Core Team and was responsible for developing strategies and executing activities to support oncology assets. During their time at Bayer, they successfully launched three new molecular entities and introduced six new indications.

Before joining Bayer, Christopher worked at Pfizer as the Director of Global Market Access for Oncology from August 2009 to September 2012. Christopher led the development and execution of market access strategies for the oncology portfolio and contributed to the launch of a new molecular entity and three new indications.

Christopher's prior experience includes roles at Bristol Myers Squibb, Ontario Ministry of Health and Long-Term Care, CombinatoRx Inc., Braun Consulting, and Vertex Partners. At Bristol Myers Squibb, they served as the Director of Global Health Outcomes for CV/Metabolics, Associate Director of Global Pricing & Reimbursement for Oncology, and Senior Manager of Health Economics, Pricing & Reimbursement.

At the Ontario Ministry of Health and Long-Term Care, Christopher worked as a Senior Economist in the Drug Programs Branch, leading pharmacoeconomic evaluations and providing policy recommendations for pricing and reimbursement.

In addition, Christopher has also worked as a Consultant at CombinatoRx Inc., Braun Consulting, and Vertex Partners, gaining valuable experience in various consulting roles.

Overall, Christopher Ngai has a comprehensive background in market access strategy, pricing, and evidence generation, with a successful track record of launching new products and indications in the pharmaceutical industry.

Christopher Ngai completed their Bachelor of Arts degree in Economics and Pre-Law Studies at Oberlin College from 1991 to 1995. Christopher later pursued a Master's degree in Economics at the University of Toronto from 1999 to 2000.